The global Plasmid DNA Manufacturing Market is estimated to be valued at US$ 901.2 Bn in 2023 and is expected to exhibit a CAGR of 22% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Plasmid DNA is circular and double-stranded DNA molecules that are self-replicating and can exist independently of or along with the chromosomal DNA. Plasmid DNA has attracted considerable interest in recent years as a potential vehicle for gene therapy and DNA vaccination. It is used in gene therapy as a carrier of therapeutic genes inside the patient’s cells. Plasmid DNA manufacturing entails cloning the gene of interest into a plasmid vector and amplifying it in a bacterial host to obtain high yields. The yields and quality obtained through current good manufacturing practices (cGMP) compliant plasmid DNA manufacturing methods allow the plasmid to be purified and formulated for safe therapeutic use in humans.
Market Key Trends:
One of the major trends in the plasmid DNA manufacturing market is the increasing R&D spending on new gene therapies. Many biotechnology and pharmaceutical companies are actively carrying out research on new gene therapies as a potentially curative treatment option for various genetic disorders and cancer. This is expected to fuel the demand for high-quality plasmid DNA for preclinical and clinical research purposes. Another key trend is the advancing technologies for large-scale plasmid DNA production. Players are focusing on optimizing fermentation and downstream purification processes to improve plasmid yields and lower manufacturing costs. This would help make gene therapies more affordable and accessible to patients.
Porter’s Analysis
Threat of new entrants: Low economies of scale needed for production and low capital requirements pose moderate threat of new entrants to the Plasmid DNA Manufacturing Market.
Bargaining power of buyers: Large number of suppliers in the market and standardized nature of products provide moderate bargaining power to buyers in the Plasmid DNA Manufacturing Market.
Bargaining power of suppliers: Critical inputs required are readily available with many alternative sources, reducing the bargaining power of suppliers in the Plasmid DNA Manufacturing Market.
Threat of new substitutes: Moderate threat of new substitutes emerging as research continues on alternative technologies for plasmid production and development.
Competitive rivalry: Intense competitive rivalry exists among the key players in the Plasmid DNA Manufacturing Market.
Key Takeaways
The global Plasmid DNA Manufacturing Market is expected to witness high growth, exhibiting CAGR of 22% over the forecast period, due to increasing demand for plasmid DNA in gene therapy and DNA vaccines.
Regional analysis
North America dominated the Plasmid DNA Manufacturing Market in 2023 and is projected to maintain its dominance over the forecast period. This is attributed to the growing gene therapy industry and strong presence of key market players in the region. However, Asia Pacific is expected to witness the fastest growth over the forecast period driven by rising R&D investment and increasing contract manufacturing activity in countries such as China and India.
Key players
Key players operating in the Plasmid DNA Manufacturing Market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it